Hepatic microfluidic bioreactor (HeMiBio)
Owner/Developer: European Commission and Cosmetics Europe
The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients.
|Channel:||Face-to-face - Website - Printed|
|Audience:||Scientists - Regulators - Industry - Researchers|
|User access:||Open access|
|Updating frequency:||Last update on 2015-11-12|
|Purpose:||Regulatory testing - Fundamental studies - Toxicological and safety evaluation - Method development|
|Technology/Tools:||Stem cells - Tissue engineering - Alternative test methods (in vitro)|
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.